Canntab Therapeutics (CSE:PILL) is pleased to announce the appointment of Bob Woloschuk to its Advisory Board. Bob has over 20 years of pharmaceutical executive experience and has a keen eye for licensing opportunities, both in Canada and in international markets.
Jeff Renwick, Chief Executive Officer and a Director, commented “We are grateful for the opportunity to add someone of Bob’s calibre to our Advisory Board, which already included some of the most impressive names in both capital markets, and cannabis research and development. Bob has a long history of successful business development within the key “Big Pharma” industry players, and has significant experience developing licensing strategies in the pharmaceutical industry. We look forward to working with Bob, who we believe adds tremendous value to our Advisory Board and the Company as a whole”.
About the Advisory Board
In addition to Mr. Woloschuk, the Canntab Advisory Board is also comprised of the following individuals:
- Sabrina Ramkellawan is the Vice President of the Clinical Research Association of Canada and the President of The Canadian Institute for Medical Advancement. She has 20 years of experience conducting clinical trials, including 7 studies on Cannabinoids and is known as a leader in the field.
- Hamish Sutherland is one of only a few individuals who has experience building a successful cannabis company. As the founding COO of Bedrocan Canada, he delivered over $400-million in returns for shareholders. He was responsible for the first legal international transfer of live cannabis plant material from Holland to Canada, and was accountable for the “greenfield” construction and commissioning of Bedrocan’s state-of-the-art automated facility, which was acquired by Tweed (now Canopy Growth) making it the leading cannabis company in Canada. Hamish is a Professional Engineer in Ontario, earned his MBA from the Schulich School of Business, and is the active Chair of the Little Geeks Foundation.
- Dr. Eric Hatashita, MD, CCFOP, FCFP, attended the University of Toronto Medical School and rose to become Chief Resident at Mt Sinai Hospital. Invited by the Kingdom of Saudi Arabia to assist in developing their Residency Training program, he lived and taught medicine overseas starting in 1996. During this time, he was chosen to become Family Physician to the Saudi Royal Family of King Abdullah from 2000 to 2005 in recognition of his clinical excellence. Returning to Toronto with his family in 2005. Dr. Hatashita brings over 30 years of diverse medical experience to a private concierge medical practice, Regal Health Services Inc., and holds the highest honours in Family Medicine, the “FCFP”.
Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab’s mission is to put the “Medical” into medicinal cannabis!
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
Canntab Therapeutics Limited
Richard Goldstein, CFO
Office: 416 957-6303
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be anticipated, estimated, or intended.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
CanBud Distribution Corporation Closes 2M Second and Final Tranche of its Oversubscribed Private Placement Offering
CanBud Distribution Corporation (CSE: CBDX) (FSE: CD0) (“CanBud” or the “Corporation”) is pleased to announce that it has closed the final tranche of its oversubscribed non-brokered private placement for aggregate gross proceeds of approximately $4,730,000 (the “Offering”).
The Corporation issued a combined total of 39,409,346 units (each a “Unit“) at price of $0.12 per Unit, with each Unit comprised of one common share in the capital of the Corporation (each a “Common Share“) and one common share purchase warrant (each a “Warrant“). Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of $0.22 within 24 months of the closing of the Offering (the “Warrant Term“), provided, however that if the closing price of the Common Shares on the Canadian Securities Exchange (the “CSE“) (or any such other stock exchange in Canada as the Common Shares may trade at the applicable time) is $0.25 or greater per Common Share for a period of five (5) consecutive trading days at any time after the closing date of the Offering, the Corporation may accelerate the Warrant Term such that the Warrants shall expire on the date which is 30 days following the date a press release is issued by the Corporation announcing the reduced warrant terms.
Thoughtful Brands Inc. (CSE:TBI)(FSE:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands) announces that the letter of intent with Franchise Cannabis Corp. (“FCC”), previously announced in January, has been terminated. The previously announced European joint venture with FCC will continue and allow the Company to launch and tailor its products to European consumer demands
In connection with termination of the merger transaction with FCC, the Company has agreed to pay FCC $100,000 in cash and to issue FCC 5,000,000 common shares of the Company at a deemed value of $0.05 per share. The common shares will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws.
Mergers and acquisitions (M&A) in cannabis space have helped boost the industry to new levels.
Strategic sale of non-core assets by Lobe adds non-dilutive capital and shareholder value
Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce, further to its press release dated February 23, 2021, that it has completed the sale to Ionic Brands Corp. (“Ionic Brands”) of Lobe’s non-core cannabis assets relating to Washington-based Cowlitz County Cannabis Cultivation Inc. (“Cowlitz”) held by Lobe’s subsidiary vendor, Green Star Biosciences Inc. (the “Transaction”).
Seattle Area Grocery Chain Metropolitan Market to Begin Carrying KOIOS and Fit Soda on March 22, 2021
Adding to its existing presence on the west coast of the United States, all five KOIOS™ flavours and all four Fit Soda™ flavours will be carried in Metropolitan Market stores beginning on Monday, March 22, 2021. Serving the Seattle-Tacoma area (population 3.87 million), Metropolitan Market is one of five chains under its parent firm Good Food Holdings, which has a total of 51 stores in California, Oregon, and Washington State.
Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that beginning on Monday, March 22, 2021, Koios’ entire line of canned beverage products will be sold at all locations of Metropolitan Market, an urban format supermarket chain in the Seattle-Tacoma area of Washington State. In Q1 2021, the Company announced multiple placements of its beverage products with regional grocers in markets on the west coast of the United States including Market of Choice in Oregon Jensen’s in Southern California and major natural grocery chain Sprouts Farmers Market which has a substantial west coast presence with over one third of its locations (360+ stores across 23 states) in California as well as Washington State 1 . The Company has also recently announced other developments relating to its expansion efforts being undertaken in 2021 such as an in-house beverage canning facility and distribution agreements with regional and national wholesale partners.